Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis
| Autor: | Nazmiye Ebru Ersoy Ortaç, Osman Özcebe, Nilgun Sayinalp, Olgu Erkin Çinar, Ahmet Çağkan İnkaya, Ibrahim C. Haznedaroglu, Salih Aksu, Elifcan Aladağ Karakulak, Mustafa Velet, Basak Sayinalp, Ayse Karatas, Serpil Öcal |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Drug medicine.medical_specialty Tuberculosis Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) media_common.quotation_subject medicine.medical_treatment Myelodysplastic 030204 cardiovascular system & hematology Article Virus Body Temperature 03 medical and health sciences 0302 clinical medicine Immune system Pandemic medicine Humans Lymphocyte Count Intensive care medicine COVID-19 Serotherapy media_common SARS-CoV-2 business.industry Immunization Passive COVID-19 Plasmapheresis Hematology Middle Aged medicine.disease Myelodysplastic Syndromes Tomography X-Ray Computed business Convalescent 030215 immunology |
| Zdroj: | Transfusion and Apheresis Science |
| ISSN: | 1473-0502 |
| DOI: | 10.1016/j.transci.2020.102821 |
| Popis: | During the ongoing COVID-19 pandemic due to the SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall be required particularly in the 'difficult-to-treat' cases of high risk group with associated comorbidities. Convalescent immune plasma therapy is a promising option as a sort of 'rescue' treatment in COVID-19 immune syndrome, where miraculous antiviral drugs are not available yet. In this report, we aim to convey our experience of multi-task treatment approach with convalescent immune plasma and anti-cytokine drug combination in a COVID-19 patient with extremely challenging comorbidities including active myeloid malignancy, disseminated tuberculosis and kidney failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect